SCHEMBL5540967

SCHEMBL5540967

O=CCCCN1CCN(C(=O)OCc2ccc(Cl)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 2/20 0.51
HRH1 P35367 2/20 0.51
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
HTT P42858 1/20 0.48
ENPP2 Q13822 2/20 0.44
PLA2G7 Q13093 1/20 0.44
MGLL Q99685 1/20 0.44
ABHD6 Q9BV23 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
TMEM97 Q5BJF2 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543682 0.96 HRH2 (0.50) HRH2HRH1ALDH1A1MAPTKMT2A
SCHEMBL5546044 0.88 MEN1 (0.54) HRH2HRH1KMT2AENPP2CYP2C19
SCHEMBL5547593 0.86 MEN1 (0.47) HRH2HRH1KMT2AENPP2SIGMAR1
SCHEMBL27610695 0.85 HRH1 (0.53) HRH2HRH1ALDH1A1MAPTKMT2A
SCHEMBL5547010 0.85 SIGMAR1 (0.45) HRH2HRH1HPGDENPP2TMEM97
SCHEMBL5543766 0.84 HRH1 (0.53) HRH2HRH1LMNATMEM97SIGMAR1
SCHEMBL5540188 0.84 HRH2 (0.52) HRH2HRH1ALDH1A1MAPTKMT2A
SCHEMBL28015142 0.84 HRH2 (0.58) HRH2HRH1ALDH1A1MAPTKMT2A
SCHEMBL5547558 0.84 MEN1 (0.53) HRH2HRH1KMT2AHTTENPP2
SCHEMBL5540041 0.83 HRH1 (0.52) HRH2HRH1LMNATMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HRH2 730/4885HRH1 668/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.